Assembly Biosciences Inc (ASMB) Actualités

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a...

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV...

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]